Specialty Medications Added to NELC’s Formulary in 2026

Name	NELC Approved Indications
Ruconest (C1 Esterase Inhibitor)	A C1 esterase inhibitor indicated in adult and adolescent patients with hereditary angioedema (HAE).
Prolia and biosimilars (Denosumab)	RANK ligand (RANKL) inhibitors indicated for treatment osteoporosis. *FDA-mandated REMS program
Xgeva and biosimilars (Denosumab)	RANK ligand (RANKL) inhibitors indicated for oncologic indications.
Vimizim (Elosulfase alfa)	A hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mycopolysaccharidosis type IV A (AKA Morquio A Syndrome). *NELC will not administer first dose; NELC patients must be > 5 years of age
Gammagard ERC (Immune Globulin 10%)	A replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients >= 2 years old. *Contains ≤ 2 µg/mL of IgA
Gammaked (Immune Globulin 10%)	An immune globulin indicated for treatment of Primary Humoral Immunodeficiency (PI) in patients >= 2 years old, Idiopathic Thrombocytopenic Purpura (ITP) in adults and children, and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in adults.
Uplizna (Inebilizumab-cdon)	A CD19-directed cytolytic antibody indicated for adults with Neuromyelitis optica spectrum disorder (NMOSD), Immunoglobulin G4-related disease (IgG4-RD), or Generalized myasthenia gravis (gMG).
Leqembi (Lecanemab-irmb)	An amyloid beta-directed antibody indicated for Alzheimer’s disease. *NELC will not administer first dose
Evenity (Romosozumab-aqqg)	A sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women.
Ilumya (Tildrakizumab-asmn)	An interleukin-23 antagonist indicated in adults for the treatment of moderate-to-severe plaque psoriasis.
Tyenne (Tocilizumab-aazg)	An interleukin-6 receptor antagonist indicated for adults with Rheumatoid Arthritis (RA) and for patients >= 2 years old with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA).
Tofidence (Tocilizumab-bavi)
Amvuttra (Vutrisiran)	A transthyretin-directed small interfering RNA indicated for adults with polyneuropathy or cardiomyopathy related to hereditary transthyretin-mediated amyloidosis.